Context Therapeutics (CNTX) Research & Development (2020 - 2026)
Context Therapeutics (CNTX) posted Research & Development of $7.0 million for Q1 2026, down 40.75% sequentially from $11.8 million in Q4 2025, and up 102.58% YoY from $3.5 million in Q1 2025.
Context Therapeutics (CNTX) Research & Development (2020 - 2026) Analysis & Trends
Context Therapeutics has reported Research & Development for 7 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Research & Development rose 102.58% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.4 million (up 46.37% YoY) and the FY2025 annual result came in at $31.9 million, up 40.33% from the prior year.
- Research & Development slipped to $7.0 million in Q1 2026 per CNTX's latest filing, from $11.8 million in the prior quarter.
- Over five years, Research & Development peaked at $16.8 million in Q3 2024 and troughed at $1.4 million in Q1 2022.
- A 5-year average of $5.1 million and a median of $3.5 million in 2025 frame the typical range for Research & Development.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 59.99% in 2024, then jumped 465.56% in 2025.
- Over 5 years, Research & Development stood at $2.1 million in 2022, then jumped by 147.19% to $5.3 million in 2023, then sank by 52.5% to $2.5 million in 2024, then soared by 370.17% to $11.8 million in 2025, then slumped by 40.75% to $7.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $7.0 million, $11.8 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 97.90 Mn |
| 10 | Context Therapeutics | 48.54 Mn | 48.54 Mn | - | 12.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.53 Mn |
| Mar 31, 2026 | 7.02 Mn |
| Dec 31, 2025 | 11.84 Mn |
| Sep 30, 2025 | 8.72 Mn |
| Jun 30, 2025 | 7.83 Mn |
| Mar 31, 2025 | 3.46 Mn |
| Dec 31, 2024 | 2.52 Mn |
| Sep 30, 2024 | 16.83 Mn |
| Jun 30, 2024 | 1.38 Mn |
| Mar 31, 2024 | 1.97 Mn |
| Dec 31, 2023 | 5.30 Mn |
| Sep 30, 2023 | 4.49 Mn |
| Jun 30, 2023 | 3.46 Mn |
| Mar 31, 2023 | 4.53 Mn |
| Dec 31, 2022 | 2.14 Mn |
| Sep 30, 2022 | 2.08 Mn |
| Jun 30, 2022 | 1.52 Mn |
| Mar 31, 2022 | 1.35 Mn |
| Dec 31, 2021 | 1.29 Mn |
| Sep 30, 2021 | 739,598.00 |